Briefing Summary: US FDA Posts Advisory Committee Materials for Two Topics, Kythera’s Deoxycholic Acid Injection for Reducing Chin Fat and Systemic Treatment of Resistant Atopic Dermatitis in Pediatric Patients – MAR 9, 2015 (DODAC)
The US FDA has posted details, including company and FDA Briefing Materials, for the Monday, March 9, 2015 Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting. In the morning session, the Committee will discuss the the safety and efficacy of deoxycholic acid injection by Kythera Biopharmaceuticals (Kythera), for the improvement in the appearance of moderate-to-severe convexity or fullness associated with submental (below the chin) fat in adults. In the afternoon session, the Committee will discuss systemic treatment of resistant atopic dermatitis in pediatric patients.